Publications by authors named "Minghong Bi"

Claim this Profile
E
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial.
Yuankai Shi, Lin Wu, Yinghua Ji, Gongyan Chen, Baolan Li, Minghong Bi

Lancet Respir Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial.
Yuankai Shi, Minghong Bi, Qingshan Li, Guolei Wang, Jianhua Chen, Shubin Tang

Cancer Pathog Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study.
Yuankai Shi, Yanzhen Guo, Xingya Li, Lin Wu, Zhaohong Chen, Minghong Bi

Lancet Respir Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors.
Mingchuan Zhao, Xichun Hu, Pengpeng Zhuang, Aiping Zeng, Yan Yu, Minghong Bi

J Bone Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study.
Dong Zhao, Minghong Bi, Xiaofei Cheng, Shuhong Wang, Huaidong Cheng

Front Immunol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.
Ying Cheng, Wei Zhang, Lin Wu, Caicun Zhou, Donglin Wang, Bing Xia, Minghong Bi

JAMA Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer.
Puyuan Xing, Shanbing Wang, Minghong Bi, Yong Liu, Jia Zeng, Biyong Ren

EClinicalMedicine· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study.
Yiwei Yao, Yong Wang, Yingying Du, Fengshou Jiang, Hui Liang, Minghong Bi

Int Immunopharmacol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
Sheng Yang, Shiman Wu, Yanqiu Zhao, Gongyan Chen, Bo Zhu, Minghong Bi

Lung Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial.
Huiping Li, Yan Huang, Zhendong Chen, Aiping Zeng, Helong Zhang, Minghong Bi

BioDrugs· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
Yuankai Shi, Shiman Wu, Ke Wang, Shundong Cang, Wenxiu Yao, Minghong Bi

J Thorac Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis.
Mingyu Wang, Depeng Lu, Minghong Bi

Int Immunopharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer.
Jingru Yang, Mingliang Deng, Minghong Bi, Yaping Wang, Xuxu Qiao

Future Sci OA· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
Yunpeng Yang, Jiya Sun, Zhehai Wang, Jian Fang, Qitao Yu, Minghong Bi

J Thorac Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Yuankai Shi, Kaijian Lei, Yuming Jia, Bingqiang Ni, Zhiyong He, Minghong Bi, Debin Sun, Bin Wang, Hongbing Duan

Cancer Commun (Lond)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial.
Tianqing Chu, Jun Lu, Minghong Bi, Helong Zhang, Wu Zhuang

Cancer Biol Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study.
Yuankai Shi, Qiqing Cai, Yu Jiang, Gang Huang, Minghong Bi

Clin Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis.
Shanshan Zhang, Minghong Bi

Ann Palliat Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Minghong Bi

J Thorac Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Downregulation of NEAT1 Suppresses Cell Proliferation, Migration, and Invasion in NSCLC Via Sponging miR-153-3p.
Lun Zhao, Minghong Bi, Haoran Zhang, Mohan Shi

Cancer Biother Radiopharm· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The expression and the role of PIWI like RNA-mediated gene silencing 3 (PIWIL3) in lung cell line.
Hai-Rong Zhou, Zhen-Yuan Gao, Ming-Hong Bi

Transl Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of case-based learning and traditional method in teaching postgraduate students of medical oncology.
Minghong Bi, Zhibiao Zhao, Jingru Yang, Yaping Wang

Med Teach· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of inhibiting ACAT-1 expression on the growth and metastasis of Lewis lung carcinoma.
Minghong Bi, Xuxu Qiao, Haoran Zhang, Huazhang Wu, Zhenyuan Gao, Zhibiao Zhao

Oncol Lett· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study.
Qingming Shi, Maojing Guan, Yong Wang, Congjing Xu, Lei Tang, Minghong Bi

Thorac Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review.
Minghong Bi, Jingru Yang, Yaping Wang, Haoran Zhang, Zhenyuan Gao

Onco Targets Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis